A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses ...

The epigenetic silencing drug for chronic hepatitis B (HBV) is built on Tune’s TEMPO epigenetic editing platform, which is delivered to cells in lipid nanoparticles. Rather than irreversibly ...

Hepatitis C virus (HCV ... Finally, innovative vaccine candidates, such as nanoparticle-based vaccines displaying permuted E1E2 glycoproteins, have shown promise in eliciting robust neutralizing ...

DSPC:Chol:PEG–C–DMA:DLin–DMA (20:48:2:30)–siRNA Hepatitis B virus (yes ... and lower toxicity in comparison with inorganic nanoparticles and viral vectors. Function-engineerable ...

Lipoxen joins with Nottingham University to deliver antiviral drugs direct to the liver by means of nanoparticles for the treatment of viral hepatitis. Lipoxen joins with Nottingham University to ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years. Tune is using a ...

Current antiviral treatments for hepatitis B can only suppress HBV replication ... and encapsulated in a delivery system called lipid nanoparticle (LNP) , EPI-003 is designed to make specific ...